Most multivitamin supplements contain between 2.5 and 25 g of B12, which is well above the RNI but considered safe due to the vitamin's low toxicity profile
Our focus is on balancing your biochemistry, rather than chasing symptoms and, consequently, providing band-aid solutions
In the human clinical trial, the trajectory of weight loss became apparent during this window
The two biggest GLP-1 peptides compared head-to-head clinical trial data, who belongs on each protocol, and how BHRC approaches the decision
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
